Please use this identifier to cite or link to this item:
|Title:||Initial experience with 225Ac-PSMA-617 in patients with advanced-stage prostate cancer|
|Authors:||SATHEKGE MIKE; KNOESEN OTTO; BRUCHERTSEIFER FRANK; REYNEKE F; KRATOCHWIL CLEMENS; LENGANA T; GIESEL FREDERIK; LAWAL I; BOSHOMANE T; VORSTER MARIZA; MORGENSTERN ALFRED|
|Citation:||JOURNAL OF NUCLEAR MEDICINE vol. 59 no. S1 p. 528|
|Publisher:||SOC NUCLEAR MEDICINE INC|
|Type:||Articles in periodicals and books|
|Abstract:||Objectives: To date, targeted α-therapy with 225Ac-PSMA-617 although still preliminary, has demonstrated strong potential to significantly benefit advanced-stage prostate cancer patients. Here we report our initial experience with 225Ac-PSMA-617 in a developing country, as one of the first groups to provide this therapy. Methods: Eligible patients with confirmed advanced-stage prostate cancer were recruited and treated with standardized activities of 8 MBq 225Ac-PSMA-617 in two month intervals. In case of favorable responses activities were decreased to 6 MBq or 4 MBq in subsequent cycles to minimize toxicity. Baseline imaging and follow-up were performed with 68Ga-PSMA-11 PET/CT prior to the next treatment cycle. Interim treatment response evaluation was based on the radiologic response, tumor marker and functional results. Results: Twenty-five patients with a mean age of 66 years were treated. A treatment activity of 8 MBq exhibited moderate toxicity with grade I-II of xerostomia in 28% of patients and induced significant antitumor response in these high-tumor-burden patients. Remarkable antitumor activity by means of objective radiologic response or tumor marker decline was observed in 85% evaluable patients. Our short-term results also demonstrate a favourable hematological and renal toxicity profile and quality of life improvements. Conclusion: Standard treatment with 8 MBq 225Ac-PSMA617 every two months seems to be clinically safe with biochemical response and imaging response in around 85% of patients along with xerostomia in 28% of patients as the notable side effect. A larger multicenter trial is needed to confirm our preliminary results which are currently limited by short follow-up and small sample size.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.